New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 21, 2014
13:39 EDTMYGNMyriad Genetics rises after court grants U. of Utah motion related to BRCA tests
A court filing in a Utah district court revealed that a judge granted the University of Utah's motion for judicial notice in support of a motion for preliminary injuntive relief in a case against Ambry Genetics. Ambry, the defendant in the case, objected to the University of Utah's characterization that a CMS reduction demonstrated Myriad Genetics' (MYGN) irreparable harm. The suit relates to a Centers for Medicare and Medicaid Services notice of a reimbursement reduction from $2,700 to $1,438.14 for BRCA1 and BRCA2 tests, effective January 1, 2014. Shares of Myriad Genetics are up 2.7% to $37.26 in afternoon trading. Reference Link
News For MYGN From The Last 14 Days
Check below for free stories on MYGN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 9, 2014
07:11 EDTMYGNMyriad Genetics presented results from myPath Melanoma test clinical study
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use